Research ethics committees SIR,-An important aspect was missed in the report of the draft circular regarding the local research ethics committee.' This document clearly states that one of the few conditions in deciding the acceptability of projects is that the financial and other rewards of the project of the doctors must be part of protocols.
There are stringent regulations for hospital consultants using NHS premises and other facilities for private work. Similar conditions should be ensured in general practice if drug trials or similar studies attract sizable income. It would be imperative for family practitioner committees and morally binding to local medical committees to see that practitioners do not use NHS paid time, premises, nurses, and other staff when carrying out paid research.
Medicine and politics SIR, -Scrutator referred to my after dinner speech to the Central Consultants and Specialists Committee.' I suggested that while most of those present had expressed opposition to the white paper and were antipathetic to the government's proposals the best way of ensuring that their fears were not realised was to participate, as leaders of our profession, in developing the detailed arrangements that are not specified within the white paper.
I emphasised the positive approach by the profession and the BMA in developing clinical audit and resource management, and the profession deserves commendation by the health authorities for the actions taken. In recent vears communication among politicians, managers in the health service, and the professionals who provide the service for the patient has been difficult. I believe this is so because politicians are vulnerable to criticism by doctors when the doctors constantly refer to examples of inadequate resources as the main cause of the problems while the managers, aware of wide discrepancies among the performance of different hospitals and services, conclude that part of the reason for the criticisms is professional intransigence to accepting reasonable management discipline and, sometimes, a tendency to overpromote a particular special interest. The development of medical audit, or clinical effectiveness, alongside resource management, or clinical efficiency, should help to bridge the gap in communication.
The main principle in the white paper that is controversial and the cause of the disagreement between the profession and the government relates to the intention to separate off those who commission health services on behalfof the local population from those who have the responsibility to provide the service. Although some feel that this separation is unnecessary, there are valid arguments for this approach, and, internationally, it is not a unique idea. If this is government policy and if it is enshrined in law then obviously we who work in the service will need to develop detailed arrangements within the system that protect the essential features of the NHS. We all recognise that our hospitals are not full of young people with hernias but contain acutely ill, chronically disabled people, young and old, and that no hospital can or should operate in isolation from its community. As long as proper arrangements and agreements are made between the commissioning authority and the provider units I see no reason to assume that care will not be improved. A commissioning authority will be concerned primarily with the overall care provided for its population and the provider hospitals will necessarily wish to play their full part in this process. General practitioner contract SIR,-Although I am unable to produce any "statistically significant figures," it seems that the profession might be in danger of alienating a previously sympathetic public if we continue in our opposition to the new contract and hence to the new style NHS. Many of my patients, friends, and neighbours have read my letters of opposition in the local press, and, though they agree that there are some possible disadvantages, they like the idea of having clinics at the surgery for specific conditions. They think that visiting the elderly should be a sine qua non of general practice (scientific evidence to its poor value notwithstanding), and all the middle aged men-that is, those over 50-whom I spoke with were enthusiastic about a sort of male MOT and thought it should be available either on Saturday morning or after 6 pm. No one was prepared to accept a comparison between a bank manager and a general practitioner, or even between a dentist and a doctor, and the reasons were very flattering to the doctors.
The businessmen among my acquaintances thought that we should be seen to be earning our index linked pension: they reckon that they are earning it for us. Five of the six whom I talked to begin work every day between 6 15 and 7 00 am, don't finish before 7 pm, and are prepared to be called in the night to give advice and go in if necessary. Two of them seek work world wide and at a late age have had to become proficient in two other languages. The money they earn is far above doctors' earnings, and they believe that we as a profession should be able to earn more.
Would we feel any better about this proposed new deal if our profits were to be trebled next vear by the review body? And if so, would this not be the satisfaction of getting the rate for the job rather than of having our mouths stuffed with gold? After all, we have asked for a trial run to be made and have been refused. Surely if we go all out to make this damned thing work and it fails then neither the public nor the government can complain. And if we become rich as a side effect -should it workwe will be seen to have deserved it. Should we not all write to our local medical committees and ask them to put a very strong case indeed for trebling the fees and allowances? 
Drug Points
Duodenal carcinoid tumour in a patient with rheumatoid arthritis receiving long term ranitidine treatment Drs P D DUANE, T M SHALLCROSS, and R V HEATLEY (Department of Medicine, St James's University Hospital, Leeds) write: We describe a case of duodenal carcinoid tumour occurring in a patient receiving long term treatment with a histamine H2 antagonist.
A 69 year old woman underwent endoscopy for a three month history of abdominal pain. A biopsy specimen was taken from a small polyp found in the first part of the duodenum. Histology showed infiltration of the deep aspects of the mucosa and submucosa by cells which had the morphological characteristics of a carcinoid tumour.
Superficial antral ulceration had been found 28 months previously at endoscopy for investigation of iron deficiency anaemia. After three months on ranitidine 150 mg twice daily she was changed to a maintenance dose of 150 mg at night. On various subsequent occasions the dosage was increased to 150 mg twice daily for recurrent episodes of abdominal pain. Rheumatoid arthritis, diagnosed in 1977, had been treated with many non-steroidal anti-inflammatory agents, including indomethacin, piroxicam, ibuprofen, diclofenac, flurbiprofen, and naproxen. Penicillamine, gold, and sulphasalazine had failed to control her arthritis. Her current treatment was hydroxychloroquine 200 mg once a day and ketoprofen 100 mg as required at night. Diabetes mellitus, diagnosed in 1982, was controlled with metformin 500 mg twice daily.
At laparotomy the duodenal nodule was resected and the liver appeared clear. Histology confirmed a non-argyrophilic, non-argentophilic, trabecular carcinoid tumour which had not invaded the muscularis propria. A urinary screen for 5-hydroxyindole acetic acid gave a negative result.
Although carcinoid tumours are the most common primary tumour of the small intestine, duodenal carcinoids are rare.' In the case of gastric carcinoids gastrin may play a part as it appears to act as a trophic hormone.2 The relation between drug induced hypergastrinaemia and carcinoids remains the subject of much debate.' Carcinoid tumours found in patients with chronic atrophic gastritis or pernicious anaemia,4 or in rats given long term H2 antagonists, appear to be confined to the gastric fundus.5 Nevertheless, the occurrence of such an unusual tumour in a patient receiving long term treatment with ranitidine leads us to suspect that the two may be interrelated. Neither the manufacturer nor the Committee on Safety of Medicines is aware of any previous reports of such an association. Sudden death after treatment with pulsed methylprednisolone Drs P V G GARDINER and I D GRIFFITHS (Drug and Therapeutics Unit, Queen Elizabeth Hospital, Birmingham B15 2TH) write: We wish to report a case of sudden death following intravenous methylprednisolone in a patient with rheumatoid arthritis. The interval between giving the drug and death was 10 days -certainly longer than in previous reports; the absence of any other known cause of death in this woman has prompted this report.
A 49 year old woman seropositive for rheumatoid arthritis was admitted for investigation of anaemia and treatment of active polyarthritis. There was no history of cardiac disease. She had been treated with penicillamine for two years and monitored appropriately. She had initially derived some benefit but later complained that the pain and stiffness were returning. A gradual fall in her haemoglobin concentration had occurred in the absence of dyspepsia or melaena. On examination she seemed anaemic, but no abnormalities were noted on abdominal or rectal examination. There was evidence of active rheumatoid arthritis. Results of cardiovascular examination were normal apart from a short systolic murmur heard at the left sternal edge. On admission her haemoglobin concentration was 76 g/l (mean corpuscular volume 673 fl, mean corpuscular haemoglobin concentration 0 29); erythrocyte sedimentation rate was 92 mm in the first hour. Iron studies confirmed iron deficiency, and faecal occult blood tests were repeatedly negative. Electrolyte, urea, and creatinine concentrations were within normal limits. Her chest x ray film and electrocardiogram were normal. Endoscopy was normal apart from mild oesophagitis.
Management included bed rest, intra-articular steroid injections (total 50 mg triamcinolone), and iron given orally. Two 500 mg pulses of intravenous methylprednisolone were given, each over a period of one hour, 48 hours apart. The patient felt well during each infusion, and no change in her pulse rate was noted. Her mobility improved considerably, and three days later she was discharged.
Ten days after the last dose of methylprednisolone she died suddenly at home. Her husband reported that she had remained well up to 50 minutes before her death-the last time she had been seen alive-and had not complained of chest pain, shortness of breath, or palpitations.
Necropsy showed terminal pulmonary congestion and deformed joints but no other relevant abnormalities. In particular, careful examination of the coronary arteries showed only early atheromatous changes, and no infarcts or emboli were noted. Examination of the valves revealed no abnormality, and it was therefore assumed that the systolic murmur had been caused by her anaemia. No gastrointestinal or intracranial abnormality was found.
Several cases of sudden death after taking dexamethasone or methylprednisolone have been reported.' 4 Some, but not all, were associated with rapid infusions or pre-existing heart disease. Studies in animals have suggested that intravenous steroids can be arrhythmogenic, and speed of administration has been suggested as an important factor.4 In a prospective study Tvede et al carried out twice daily electrocardiography after giving 500 mg methylprednisolone intravenously to five patients.' Bradycardia was documented in all patients (but was symptomatic in only one), and the pulse rate of all patients did not return to normal until the seventh day. A terminal arrhythmia has rarely been documented, but in the case reported by Moses et al junctional bradycardia was noted. ' The fact that "silent" bradycardia can persist for at least six days after taking methylprednisolone suggests that we may be overlooking "late" deaths related to this treatment. Laxative induced magnesium poisoning in a 6 week old infant Drs LILIAS H ALISON and D BULUGAHAPITIYA (Rotherham District General Hospital, Rotherham S60 2UD) write: Hypermagnesaemia is a recognised complication of treatment with magnesium preparations but has rarely been reported in paediatric practice. We describe a baby who had life threatening apnoeas due to magnesium hydroxide used to treat constipation. A 6 week old, previously healthv boy was admitted with apnoeic episodes. In the week before presentation he had become constipated and had been prescribed magnesium hydroxide mixture 550 mg/10 ml (Milk of Magnesia) for 48 hours in doses of one third of a 5 ml teaspoon with feeds, 16 doses being given in 48 hours. Trwelve hours before presentation he became increasingly lethargic and then had numerous apnoeic episodes in the hour before admission. At presentation he was drowsy and had few spontaneous movements. Respiratory effort was poor and one further episode of apnoea was witnessed. His pupils were dilated and reacted sluggishly to light. He was hypotonic and areflexic. His pulse and blood pressure were normal. Electrocardiographv confirmed sinus rhythm.
Biochemical investigations showed hypermagnesaemia with metabolic alkalosis: serum sodium concentration 136 mmol/l; serum potassium 3-6 mmol/l; plasma urea 6-9 mmol/l; plasma creatinine 44 [tmol/l; Magnesium toxicity is well described in adults and is usually iatrogenic.' It rarely occurs in the absence of intestinal or renal disease. Hypermagnesaemia in children is rare. Neonatal hypermagnesaemia is a recognised complication of treating maternal pre-clampsia in labour with large doses of parenteral magnesium. It has also been reported in a neonate receiving tolazoline and given antacids containing magnesium to protect against gastrointestinal haemorrhage.' Hypermagnesaemia causes neuromuscular dysfunction by inhibiting acetylcholine release at the neuromuscular junction.' Values above 3 mmolUl produce loss of deep tendon reflexes, hypotonia, and progressive paralysis. Values of 5 mmol/l or more may cause respiratory arrest, heart block, and asystole.4
Standard paediatric textbooks still recommend magnesium hydroxide in doses of one to two teaspoons for unresponsive or severe constipation in infancy." The manufacturers, however, have no recommended dosage to children under 1 year. This case shows the dangers of prescribing magnesium compounds to infants. Caution should be exercised in prescribing drugs "with feeds" in infancy, as their frequent feeding pattern may result in drug toxicity. 
